TGTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 16, 2022 in the Class Action Filed on Behalf of TG Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - August 9, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TG Therapeutics, Inc. (NASDAQ: TGTX) alleging that the Company violated federal securities laws.

Class Period: January 15, 2020 to May 31, 2022
Lead Plaintiff Deadline: September 16, 2022
No obligation or cost to you.

Learn more about your recoverable losses in TGTX:
https://www.kleinstocklaw.com/pslra-1/tg-therapeutics-loss-submission-form?id=30683&from=5

TG Therapeutics, Inc. NEWS - TGTX NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in TG Therapeutics you have until September 16, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased TG Therapeutics securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the TGTX lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133232